hrp0095p1-228 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Effect of burosumab treatment on phosphate metabolism and bone health in patients with X-linked hypophosphatemic rickets (XLH). Preliminary data within an Italian sample.

Baroncelli Giampiero , Comberiati Pasquale , Rita Sessa Maria , Pelosini Caterina , Grandone Anna , Camodeca Rosanna , Emma Francesco

XLH is the commonest inherited form of rickets. Impaired regulation of fibroblast growth factor 23 (FGF23) due to PHEX gene mutation leads to reduced tubular reabsorption of phosphate (TmP/GFR) and 1,25-dihydroxyvitamin D (1,25(OH)2D) synthesis with hypophosphatemia. Patients show rickets and osteomalacia, bone and muscular pain, stunted growth, and reduced quality of life. We report preliminary data on burosumab therapy in a selected sample of Italian patients.<p class="a...

hrp0086p1-p621 | Growth P1 | ESPE2016

Final Height after Growth Hormone Treatment in Children with Chronic Renal Failure

Lonero Antonella , Bizzarri Carla , Delvecchio Maurizio , Emma Francesco , Strologo Luca Dello , Cappa Marco

Background: Growth retardation is seen in about 30% of children with chronic renal failure (CRF). Under-nutrition, anaemia, secondary hyperparathyroidism, acidosis, corticosteroid therapy and abnormalities in the GH/insulin like growth factor system have been implicated. Recombinant GH (rGH) therapy is recommended in children showing failure to maintain a normal height velocity despite optimized primary treatments.Objective and hypotheses: It has been de...